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The Hippo pathway is an oncosuppressor signalling cascade that plays a major role in the
control of cell growth, tissue homoeostasis and organ size. Dysregulation of the Hippo
pathway leads to aberrant activation of the transcription co-activator YAP (Yes-associated
protein) that contributes to tumorigenesis in several tissues. Here we identify glucocorticoids
(GCs) as hormonal activators of YAP. Stimulation of glucocorticoid receptor (GR) leads to
increase of YAP protein levels, nuclear accumulation and transcriptional activity in vitro and
in vivo. Mechanistically, we find that GCs increase expression and deposition of fibronectin
leading to the focal adhesion-Src pathway stimulation, cytoskeleton-dependent YAP activa-
tion and expansion of chemoresistant cancer stem cells. GR activation correlates with
YAP activity in human breast cancer and predicts bad prognosis in the basal-like subtype. Our
results unveil a novel mechanism of YAP activation in cancer and open the possibility to
target GR to prevent cancer stem cells self-renewal and chemoresistance.
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C
ell proliferation, tissue growth and organ size control
are primarily regulated by the Hippo signalling, a pathway
originally discovered in Drosophila melanogaster,
and highly conserved in higher eukaryotes1. The core of the
mammalian Hippo pathway is a serine/threonine kinase cassette
represented by the Ste20-like MST1/2 (Hippo in Drosophila)
kinases and the large tumour suppressor LATS1/2. Activated
MST1/2 in association with the adaptor protein Salvador
(Sav1) phosphorylate and activate the downstream kinases
LATS1/2, which in turn phosphorylate and inhibit the Hippo
pathway nuclear effectors YAP (Yes-associated protein) and
TAZ (transcriptional co-activator with PDZ-binding motif).
While phosphorylated YAP/TAZ are retained in the cytoplasm
and directed toward proteasome-dependent degradation, depho-
sphorylated YAP/TAZ localize in the nucleus and function as
transcription co-activators for the TEAD family of transcription
factors to induce gene expression thereby promoting the cell
growth, proliferation and survival2,3.
Disruption of Hippo signalling in mouse models promotes
tumour formation, while transgenic YAP overexpression in
mice results in hyperplasia and eventual tumour development4,5.
Aberrant activation of YAP and TAZ has been observed in many
human cancers, including high-grade and metastatic breast
cancer, and it is associated with tumour initiation, progre-
ssion and metastasis6,7. The YAP/TAZ-induced transcriptional
program leads to an increase in cell proliferation, migration, self-
renewal of cancer stem cells (CSCs), epithelial-to-mesenchymal
transition and drug resistance, making these transcription
co-activators attractive targets for cancer therapies1,3.
While the core components of the Hippo pathway are
well established, a number of additional upstream regulators
are emerging. YAP/TAZ, in fact, have turned out to be primary
sensors of a variety of signals generated on cell–cell contacts,
by adhesion and apical–basal polarity proteins, by the mechanical
cues of the neighbouring cells and the extracellular matrix (ECM),
as well as in relation to the metabolic state of the cell2,3,8.
Moreover, a number of diffusible extracellular ligands have
been recently entered into the list of YAP/TAZ regulators. In
this context, it has been demonstrated that some signalling
molecules, among which lysophosphatidic acid and epinephrine,
control YAP/TAZ via G-protein-coupled receptors9. Also
oestrogens have been shown to strongly impact on YAP/TAZ
regulation, but only through the membrane-associated G-protein-
coupled oestrogen receptor10. However open questions remain
on whether YAP/TAZ are controlled by hormones acting through
nuclear receptors.
Here, we identify glucocorticoids (GCs) as hormonal activa-
tors of YAP in breast cancer cells. We demonstrate that
GCs treatment promotes fibronectin deposition, focal adhesion-
dependent activation of Src and the remodelling of the actin
cytoskeleton, which ultimately results in sustained YAP activity.
Moreover, we find that in breast cancer cells the activation
of glucocorticoid receptor (GR) is fundamental for CSCs self-
renewal and chemoresistance and that this effect is the conse-
quence of the transcriptional activity of activated YAP.
Our results unveil an unpredicted layer of YAP regulation
and put the GR–YAP axis at the cornerstone of a potential
new therapeutic strategy to specifically target CSCs in breast
cancer.
Results
GCs induce activation of the Hippo transducer YAP.
To identify novel signalling pathways able to control YAP acti-
vation in breast cancer we performed a high-content, fluorescence
microscopy-based, high-throughput screening using a library
of FDA: Food and Drug Administration (FDA)-approved drugs
composed of a collection of 640 clinically used compounds with
known and well-characterized bioactivity, safety and bioavail-
ability11. The activation of YAP observed in human cancers is
linked to increased levels of YAP protein that accumulate in the
nucleus12. Therefore, we monitored the effect of each compound
of the library on YAP protein levels in the triple-negative breast
cancer cell line MDA-MB-231. Drugs were added to the culture
medium for 24 h and total YAP protein amount was detected by
immunofluorescence followed by automated quantification of the
YAP-relative signal at single-cell level (Supplementary Fig. 1a).
With this analysis, we identified drugs that either reduced or
increased YAP protein amount (Fig. 1a). Interestingly, the
compounds with the strongest effect in increasing YAP protein
levels belong to the class of synthetic GCs (Fig. 1a,b).
Betamethasone (BM) was among the strongest hits and,
together with hydrocortisone (HC) and dexamethasone (DM),
was selected for further analysis.
Natural GCs, such as cortisol, are a class of steroid hormones
acting through specific nuclear receptors and playing impo-
rtant roles in various physiological processes, such as meta-
bolism, immune response and development13. Owing to their
anti-inflammatory and immunosuppressive actions, synthetic
GCs have been widely used in the treatment of inflammatory
and autoimmune diseases14.
To evaluate the response of MDA-MB-231 cells on GCs
stimulation, we used the GCs-responsive reporter MMTV-luc15.
Treatment with BM for 24 h led to strong increase of luciferase
signal, which was completely prevented by concomitant
administration of the GC and progesterone receptors inhibitor
RU486 (Supplementary Fig. 1b). To validate the results of the
screening we monitored YAP protein levels by western blot (WB)
in MDA-MB-231 cells, in Ras-transformed MCF10A-T1k
(hereafter MII) cells and in immortalized normal mammary
MCF10A cells on treatment with GCs16. BM led to a
GR-dependent increase of YAP protein levels in all the
investigated cell lines (Fig. 1c), an effect not observed for
the YAP paralog TAZ (Supplementary Fig. 1c).
In cells, YAP acts mainly as TEADs transcription co-factor
inducing the expression of several genes17. To determine whether
the GCs-induced increase of YAP levels was associated with
its functional activation, we monitored the expression of
YAP target genes (Ankrd1, Cyr61 and Ctgf) in MDA-MB-231
cells, on administration of GCs18. Interestingly, along with
increased expression of GILZ, a well known GC-responsive
gene19, BM treatment increased the expression of YAP target
genes and this effect was prevented by RU486 co-treatment
(Fig. 1d,e). Moreover, short interfering RNA (siRNA)-mediated
knockdown of YAP, but not of TAZ, prevented the induction
of YAP targets, while having no effects on GILZ expression
(Fig. 1d,e; Supplementary Fig. 1d,e). To investigate whether
GCs could regulate YAP transcriptional activity in vivo,
we systemically injected DM in C57Bl/6 mice and after 16 h we
measured YAP transcriptional activity in the mammary tissue.
We used the expression levels of YAP target genes Ccnd1 and
Ctgf as reporters of YAP activity, as they have been previously
used with success to monitor YAP activation in vivo and
have been reported to be expressed in breast tissue20,21; GILZ was
used as a control for GR activation. Interestingly, BM treatment
led to significant increase in Ccnd1 and Ctgf expression in
the mammary tissue (Fig. 1f). Taken together, these results
support the notion that GCs activate YAP in mammary epithelial
cells in vitro and in vivo.
GR controls YAP in breast cancer cells. Natural GCs are
cholesterol-derived hormones released in the serum. Their
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synthesis and relapse are under circadian and stress-associated
regulation exerted by the hypothalamic–pituitary–adrenal axis22.
Both natural and synthetic GCs mediate their effects on target
cells by binding to GR and inducing its translocation into
the nucleus, where it acts as a transcription factor that positively
or negatively regulates the expression of GC-responsive genes22.
Several soluble serum factors, such as G-protein-coupled receptor
agonists, cytokines and growth factors, have been shown
to control YAP activity in cancer cells2; thus, we hypothesized
that, acting through GR, GCs may represent a novel class
of serum regulators of YAP. To test this hypothesis, we first
assessed the ability of serum GCs to activate endogenous GR in
breast cancer cells. As expected, in serum-starved MDA-MB-231
cells GR localized mainly in the cytoplasm in an inactive state
(Fig. 2a). On addition of 10% fetal bovine serum (FBS) to cells for
24 h a clear nuclear localization of GR was observed in almost
50% of the cells while, after BM treatment, all the cells (100%)
scored positive (Fig. 2a; Supplementary Fig. 1f). To assess whether
serum GCs control YAP activation in breast cancer cells,
we knocked down GR by siRNA transfection in MDA-MB-231,
BT-549 and MII cells grown in 10% FBS. Interestingly,
GR silencing led to a strong reduction of the protein levels of
YAP, but not of TAZ, and this effect was due to increased the
protein degradation (Fig. 2b; Supplementary Fig. 1g,h). Moreover,
GR silencing reduced YAP transcriptional activation, as assayed
by monitoring the reporter activity of a YAP-responsive 8XGTII-
luc construct and the expression levels of YAP target genes
(Fig. 2c,d)11,18. Altogether these results demonstrate that
GR regulates YAP protein levels and transcriptional activity in
breast cancer cells.
GCs induce YAP nuclear localization. The analysis of
YAP subcellular localization showed that all the GCs of the drug
collection used for the screening increased the percentage of
cells displaying nuclear-localized YAP (Fig. 3a)11. Moreover,
validation experiments confirmed that BM induces YAP nuclear
localization in serum-starved cells (Fig. 3b,c; Supplementary
Fig. 2a)9. As YAP activity is tightly controlled through
its phosphorylation-dependent nucleocytoplasmic shuttling6,23,
we next monitored the levels of YAP phosphorylation on Ser-127,
a post-translational modification associated to YAP cytoplasmic
retention23. Interestingly, on BM treatment, MDA-MB-231 and
MII cells displayed a strong decrease of YAP phosphorylation
on Ser-127 along with increased YAP protein levels (Fig. 3d)9.
In line with this, BM treatment rescued YAP nuclear localization
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Figure 1 | Glucocorticoids induce activation of the Hippo transducer YAP in vitro and in vivo. (a) Results of the high-content screening. YAP fluorescence
intensity is relative to DMSO-treated samples. (b) Representative images from the screening. MDA-MB-231 stained for Hoechst (blue) and YAP (red) after
treatment with DMSO or the indicated glucocorticoids are shown. Experiment repeated two times. Scale bars, 100mm. (c) MDA-MB-231, MCF10A and
MII cells were treated with BM 1 mM alone or in combination with RU486 1 mM for 24 h. Representative blots are shown. Experiment repeated three times.
(d) Quantitative PCR with reverse transcription (qRT–PCR) analysis of MDA-MB-231 transfected with indicated siRNA for 48 h and treated with 1 mM
BM alone or in combination with RU486 1 mM for 24 h. siCTL is control siRNA. Error bars represent mean±s.d., from n¼ 3 biological replicates. siYAP
sequence is siYAP#1. (e) MDA-MB-231 cells were treated as in d, representative blots are shown. Experiment repeated three times. siYAP sequence is
siYAP#1. (f) qRT–PCR analysis of breast epithelial tissue from control (NT) or dexamethasone (DM)-treated mice. Error bars represent mean±s.d., n¼4
mice per group. *Po0.05, **Po0.01; two-tailed Student’s t-test is used throughout.
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in cells grown at high confluence, a condition known to inhibit
YAP nuclear localization in a phosphorylation-dependent
manner (Fig. 3e; Supplementary Fig. 2b).
The LATS1/2 kinases are key components of the Hippo
pathway and are known to phosphorylate YAP on several
residues, including Ser-127. Thus, we sought to determine
whether LATS1/2 were involved in the regulation of YAP locali-
zation by GCs. Of note, while RU486 treatment induced
YAP cytoplasmic localization in BM-treated cells, LATS1/2
knockdown completely prevented this effect (Fig. 3f; Supple-
mentary Fig. 2c). To confirm the role of LATS1/2 in BM-induced
YAP nuclear localization, we transiently transfected MDA-MB-
231 cells with a construct expressing a mutant form of
YAP (YAP-5SA) able to escape LATS1/2-mediated phosphoryla-
tion24. YAP-5SA was almost completely insensitive to RU486
treatment in BM-treated cells, thus suggesting that GCs regulate
YAP subcellular localization in a LATS1/2-dependent manner
(Supplementary Fig. 2d). Consistently, in parallel with a decrease
in YAP phosphorylation, BM caused a reduction of the
phosphorylated and active form of LATS1 (Fig. 3g), confirming
that GCs inhibit the Hippo pathway activation.
GR activates YAP by inducing FN1. To explore the molecular
mechanisms underlying YAP activation in response to GR
stimulation, we monitored the time course of GR and YAP
activation after BM treatment using GILZ (target of GR) and
Ankrd1 (target of YAP) messenger RNA (mRNA) levels as read
outs. As shown in Fig. 4a,b, GR nuclear translocation significantly
anticipated YAP nuclear accumulation. Moreover, analysis of
GILZ and Ankrd1 mRNA levels showed that GR and YAP are
not concurrently activated by BM treatment (Fig. 4c). These
results, together with the evidence that YAP mRNA levels are not
significantly affected by GCs (Supplementary Fig. 3c), suggest
that YAP is not a direct target of GR and are consistent with a
scenario, in which YAP is activated as an indirect consequence
of the GR transcriptional activity. To identify GR target genes
involved in the GC-dependent activation of YAP, we examined
the genes induced in MDA-MB-231 cells on DM treatment
as annotated in published data set25 and we found an enrichment
in genes involved in cellular adhesion (Supplementary Tables 1,
4 and 5)26. We focused our attention on fibronectin 1 (FN1),
a glycoprotein that is essential for establishing cell adhesion to
ECM and spreading (Supplementary Table 5). Recently, cell
adhesion to fibronectin has been found to regulate Hippo sign-
alling and YAP activation through mechanical stimulation of
cells27. We also analysed the GR chromatin immunoprecipitation
(ChIP)-Seq data set of Dex-stimulated A549 cells derived from
the ENCODE project and we identified and validated a stringent
ChIP-Seq peak in the FN1 promoter, supporting that FN1 is a
direct target of GR that could activate YAP by reinforcing cell
adhesion to ECM (Supplementary Fig. 3a,b). To test this
hypothesis, we monitored FN1 mRNA levels in MDA-MB-231
cells after BM treatment. Of note, BM induced a strong increase
of FN1 mRNA and protein levels, as well as its extracellular
deposition, in a GR-dependent manner (Fig. 4d–f; Supplementary
Fig. 3d,e). In line with increased fibronectin expression,
microscopy analysis confirmed that cells receiving BM under-
went marked morphological changes with a clear increase in
cell size and spreading (Fig. 4g). These results strongly suggest
that GR-induced FN1 expression and deposition might alter the
ECM composition in the local microenvironment with a conse-
quent impact on cell adhesion which, in turn, could lead to
the YAP activation27. To test this hypothesis, we treated cells
with BM in combination with a synthetic peptide (the Arg -Gly
-Asp (RGD) containing peptide) that competing with ECM
ANK
RD1 CTG
F
CYR
61 GR
0
0.2
0.4
0.6
R
el
at
iv
e 
m
R
N
A 
le
ve
ls
1.0
0.8
siCTL
siGR
MDA-MB-231 d
0
20
40
60
80
100
c
b
siCTL siGR
Actin
YAP
GR
a
BT-549
–FBS +FBS
Merge
GR
Hoechst
MDA-MB-231
siCTL siGR
MDA-MB-231 BT-549
8X
G
TI
I-l
uc
 (%
 of
 co
ntr
ol)
siCTL
siGR
siCTL siGR
MCF10A-MII
**
**
**
**
**
**
–55 kDa
–72 kDa –72 kDa
–72 kDa
–55 kDa –55 kDa
–72 kDa –72 kDa
–72 kDa
Figure 2 | Glucocorticoid receptor controls YAP activity in breast cancer cells. (a) Representative images of immunofluorescence in MDA-MB-231 cells.
Cells were serum starved or grown in 10% FBS for 24 h. Experiment repeated three times. Scale bars, 15mm. (b) MDA-MB-231, BT-549 and MII cells were
transfected with control (siCTL) or glucocorticoid receptor (siGR) siRNA for 48 h. Representative blots are shown. Experiment repeated three times.
(c) MDA-MB-231 and BT-549 cells were transfected with control (siCTL) or glucocorticoid receptor (siGR) siRNA. The day after, cells were transfected
with 8XGTII-luc reporter. After 24 h cells were collected. Data are normalized to siCTL. Error bars represent mean±s.d., from n¼ 3 biological replicates.
(d) Quantitative PCR with reverse transcription analysis of MDA-MB-231 transfected with control (siCTL) or glucocorticoid receptor (siGR) siRNA for 48 h.
Error bars represent mean±s.d., from n¼ 3 biological replicates. *Po0.05, **Po0.01; two-tailed Student’s t-test is used throughout.
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proteins’ binding to integrin—impedes the adhesion of cells to
ECM. Of note, RGD co-treatment prevented YAP dephos-
phorylation, nuclear translocation and Ankrd1 upregulation
induced by BM (Fig. 4h–j). In line with this evidence, FN1 and
integrin aV siRNA transfection prevented the YAP activation
downstream of GR stimulation (Supplementary Fig. 3f,g),
demonstrating that FN1 acts as an effector of GR signalling to
stimulate YAP function.
GCs activate YAP via actin cytoskeleton remodelling. Increased
matrix stiffness is a feature of several solid tumours, and
the integrated cooperation of mechanical and diffusible signals
is required to maintain this physical property within the tumour
mass18,28,29. YAP has been described as a sensor and transducer
of mechanical stimuli. Indeed, in cells grown on high-rigidity
substrate under high mechanical tensions generated by
actin stress fibres YAP localizes in the nucleus and activates
its transcriptional program18,27. In this context, tension imposed
by integrin-mediated cell adhesion to fibronectin leads to
FAK/Src-mediated cytoskeleton rearrangement, cell spreading
and LATS1/2-dependent YAP nuclear localization27,30,31.
Moreover, actin cytoskeleton and Src functions are required
for the YAP activation by stiff matrices32. Thus, it is conceivable
that GC-induced YAP activation could be triggered by
the increased deposition of fibronectin, which in turn stimulates
the intracellular integrin–FAK–Src signalling. To test this hypo-
thesis, we analysed these cascade of events by staining
focal adhesions, by vinculin immunofluorescence in BM-treated
MDA-MB-231 cells. As shown in Fig. 5a, along with
the induction of YAP nuclear localization, BM treatment
elicited a marked increase of the number of focal adhesions,
which was completely prevented by the GR inhibitor RU486
(Supplementary Fig. 4a). Consistently, BM-induced Src
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activation, as demonstrated by increased phosphorylation of
Src (on Y-416) and of FAK (on Y-925, a Src-specific
phosphorylation site; Fig. 5b; Supplementary Fig. 4b). To prove
the involvement of the focal adhesions and of Src pathway
activation in YAP nuclear localization downstream of GR, we
pharmacologically inhibited Src activation in BM-treated
cells. Strikingly, the nuclear translocation and activation of
YAP induced by BM was completely prevented by the
two Src inhibitors dasatinib and saracatinib, in a LATS1/2-
dependent manner (Fig. 5c–f). Similarly, treatment with a
FAK inhibitor (PF573228) or growing cells in suspension
prevented YAP activation on GC treatment (Fig. 5c–e;
Supplementary Fig. 4c). Interestingly, while BM-induced
LATS1 inhibition, which was prevented by both Src and
FAK inhibition, MST1/2 activity remained unchanged after
these treatments (Supplementary Fig. 4f). These results
demonstrate that, downstream of GR stimulation, Src signalling
is required for YAP nuclear translocation and activation.
BM treatment also caused a strong increase in the number
of F-actin stress fibres, which are downstream of Src (Fig. 5g;
Supplementary Figs 4d and 5). Notably, inhibition of actin poly-
merization by latrunculin A treatment prevented YAP activa-
tion induced by BM, leaving totally unaffected GR activation
(Fig. 5h–j; Supplementary Figs 4e and 5)33. Moreover, RGD,
dasatinib and PF573228 treatments, as well as ablation of
FN1 or intergrin aV by siRNA transfection prevented stress
fibres formation downstream of GR stimulation (Suppleme-
ntary Figs 3f,g and 5). Taken together, these data clearly
demonstrate that on GR stimulation, activation of focal
adhesion signalling caused by increased FN1 deposition leads
to YAP activation via Src-dependent actin cytoskeleton
remodelling.
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YAP is required for GC-induced stem cell traits. Expression
of YAP in breast basal cells triggers CSC formation and
maintenance via acquisition of stem cell traits34. On the basis
of our results, we hypothesized that the endocrine control exerted
by GCs on YAP might have an impact in sustaining the
self-renewal potential of breast CSCs35. To assess whether
the GR–YAP axis plays a causal role in defining CSC traits,
we tested the effect of BM on the self-renewal potential of
mammary epithelial cells from a panel of different basal breast
cancer cell lines by testing their capacity to form and
propagate mammospheres in vitro36–38. Strikingly, a 5 days
GC pre-treatment39 of MII, MDA-MB-231, BT-549 and
SUM159 cells grown in 2-day culture conditions, significantly
increased the efficiency of secondary mammosphere formation
(Fig. 6a,b), suggesting that activation of GR signalling poten-
tiates CSCs’ self-renewal. In line, the treatment increased the
percentage of CD44þ /CD24 cells, a population of cells with
high self-renewal potential, in a GR-dependent manner
(Supplementary Fig. 6a)34. To further confirm these data, we
investigated the involvement of GR signalling in CSC traits
in human breast tumours. To this aim, we retrieved two
signatures of GR activation from two independent published
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datasets obtained from GC-stimulated genes in MDA-MB-231
and A549 cells25,40 and found that GR transcriptional activity
is associated with molecular signatures of breast stem cells in a
metadata set of 3,661 primary human breast cancers
(Supplementary Fig. 6e)41,42.
To study the impact of YAP in GC-induced self-renewal,
we performed mammosphere assays on YAP knockdown and
HC treatment. Of note, YAP ablation completely prevented
the increase of mammospheres number induced by HC (Fig. 6b;
Supplementary Fig. 6b). Moreover, to formally prove that
the effect of GCs on mammosphere formation and expansion
was dependent on YAP nuclear activation, we stably transduced
MII cells with the constitutively active form of YAP (YAP-5SA)
and found that the transduced cells were completely refractory
to GC treatment being able to form mammospheres in
the absence of HC in the medium (Fig. 6b).
To gain insights into the mechanism of CSC expansion by
GCs via YAP activation we analysed the list of genes induced
by GC treatment (Supplementary Table 1) and identified
Slug (also known as SNAI2), a crucial determinant of breast
CSCs traits43, among the GC-induced genes. Of note, Slug is a
known YAP target gene17,44,45, therefore we hypothesized
that GC could sustain the expansion of CSCs by increasing
the expression of Slug in a YAP-dependent manner. To test
this, the expression of Slug was analysed in cells treated with
BM. As shown in Fig. 6c, BM induced a strong increase of
Slug mRNA levels, while YAP depletion completely prevented
this effect. In line with this, Slug knockdown efficiently inhibited
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the positive effects of BM on mammosphere formation (Fig. 6d;
Supplementary Fig. 3f), suggesting that downstream of YAP, Slug
acts as an effector of the GC signalling to establish CSCs traits.
Next, we wanted to test whether GR affects the ability
of tumour progenitor cells to seed tumours in vivo by serial
dilution transplantation experiment of MDA-MB-231-shCTL
and MDA-MB-231-shGR cells in mice. Of note, GR depletion
reduced the tumour size and the frequency of tumour engraft-
ment (Fig. 6e). As expected, YAP and Slug protein levels were
reduced in tumours from MDA-MB-231 cells depleted of
GR (Fig. 6f). These results are consistent with the in vitro results
described above and demonstrate that GR signalling is required
for the maintenance of tumour-initiating cells.
Finally, we assessed whether inhibition of the entire GR/YAP
axis might represent a pharmacological strategy to specifically
target CSCs in breast cancer. This was accomplished using
drugs acting at three different steps (Fig. 6g): GR inactivation by
means of RU486, Src inactivation by dasatinib and YAP
inactivation by verteporfin, which inhibits the physical
YAP–TEAD interaction46. Interestingly, all these inhibitors
dramatically interfered with the BM-induced self-renewal of
CSCs in MDA-MB-231 and MII cells (Fig. 6h; Supplementary
Fig. 6c). Similar results were obtained on FN1 knockdown
(Supplementary Fig. 6d). Overexpression of nuclear YAP rescued
the effect of RU486 and dasatinib but not of verteporfin,
consistently with our results indicating that GR and Src act
upstream of YAP (Fig. 6h).
GR-dependent YAP activation is involved in chemoresistance.
To assess whether GR signalling correlates with YAP activation
in human breast cancer, we stratified patients from a meta-data
set of primary human breast tumours into groups displaying
high or low GR pathway activation and assessed the level of
YAP activity using a published YAP signature16. As shown in
Fig. 7a, patients classified as having high GR activation also
showed high YAP activity, thus confirming our in vitro results
(Fig. 7a; Supplementary Fig. 6f).
In estrogen receptor (ER)-negative breast cancers, including
triple-negative breast cancer and in prostate cancer, expression
levels of GR correlate with bad prognosis of chemotherapy-
treated patients, suggesting a role for GR in tumour aggressive-
ness and resistance to drug treatment25,47,48. However, although
this evidence has been well documented, the mechanisms
underlying the GR-associated chemoresistance in breast cancer
are largely unknown. In addition to self-renewal, resistance to
standard chemotherapy (for example, taxanes treatment) is
another well-established feature of CSCs49. On the basis of our
results, we hypothesized that the GC-induced chemoresistance
could be mediated by YAP that acts downstream of GR to fuel
the expansion of drug-resistant CSCs. To test this hypothesis,
we treated MDA-MB-231 cells with paclitaxel (PX) for 48 h
and assessed cell death by monitoring the cleavage of PARP-85,
a marker of apoptosis. As expected, PX elicited apoptosis
while co-treatment with BM efficiently prevented cell death in a
GR-dependent manner (Supplementary Fig. 6g). To demonstrate
the involvement of YAP in BM-induced cell survival we knocked
down YAP in PX-treated MDA-MB-231 cells and found that
YAP silencing rescued drug-induced cell death in BM-treated
cells (Fig. 7b). This evidence prompted us to investigate
the consequences of the GR–YAP axis abrogation on CSCs
expansion during drug treatment. To this aim, we elicited
mammosphere formation from MII and MDA-MB-231 cells
treated with PX. As expected, PX promoted a slight increase
of mammosphere formation efficiency due to the sele-
ctive expansion of chemotherapy-resistant CSCs50 (Fig. 7c).
However, the pharmacological inhibition of the GR pathway
by RU486 co-treatment completely blunted this effect, suggesting
that GR is responsible for the expansion of CSCs during
PX treatment (Fig. 7c). Moreover, YAP-5SA overexpression
completely rescued CSC expansion in the presence of PX and
RU486, thus confirming the role of YAP as an effector of the
GR in inducing CSC self-renewal and chemoresistance (Fig. 7c,e).
In line with these results, we stratified patients based on
the activation level of GR and we found that high activity of
GR was associated with shorter overall survival in basal-like
breast tumours (Fig. 7d).
Discussion
In this report, we demonstrate that YAP is a sensor of
GR signalling in breast cancer cells. Mechanistically, we found
that GR signalling affects the mechanical properties of the tumour
microenvironment, ultimately promoting YAP nuclear accumu-
lation and activation. On hormonal stimulation, GR induces
expression and extracellular deposition of fibronectin, leading
to increased number of focal adhesions and cell spreading.
These events, in turn, activate Src and induce actin cytoskeleton
rearrangements that promote YAP activation. The GC–GR–YAP
axis is required for and/or enhances self-renewal of breast
CSCs and YAP is responsible for the GC-induced resistance
to chemotherapy drugs (Fig. 7c).
Alterations of the mechanical properties of the ECM, that
is, stiffness and elasticity, can be induced by cancer cells
themselves or by stromal cells and represent mechanical inputs
that profoundly affect crucial biological aspects of tumour
development, such as cell proliferation, differentiation and
apoptosis29. Breast tumours are typically stiffer than the normal
tissue and this feature is commonly used as a diagnostic tool to
screen patients for early lesions51. The mechanisms underlying
how cells sense or alter the mechanical properties of the
microenvironment in response to certain stimuli remain largely
unknown, particularly in the context of epithelial cells. In this
regard, our results establish a direct relationship between the
endocrine system and the mechanical features of the ECM,
opening a scenario in which aberrant endocrine activation of
GR has a relevant impact on tumour microenvironment and,
as a consequence, on cancer aggressiveness.
Cells can sense mechanical signals from ECM through
various physical contacts, among which integrin-based cell–
matrix focal adhesions. Our data indicate that GR stimulation
activates YAP through a hormonal and cell-autonomous manner
and involves intracellular signalling pathways triggered by
the cell–ECM interplay. On sensing forces, cells react by
increasing tension within the intracellular actin cytoskeleton.
This mainly occurs through the activation of two families of
proteins: the Src kinases and the RhoGTPases. Signalling
pathways activated by these enzymes have been found to mediate
the effects of ECM rigidity on YAP18,27,32,52. Although RhoA
activation on GC treatment has been previously reported53, in
this study the main route through which GR signalling acts
to activate YAP relies on integrin/Src activation and F-actin
polymerization. As the signalling pathways activated by
Src kinases and RhoGTPases are connected by extensive
crosstalk, further investigations are needed to clarify the exact
role of RhoGTPases in this context.
Interestingly, recent work reported that, through YAP/TAZ
activation, ECM stiffness profoundly affects the sensitivity
of breast cancer cells to therapeutics54. In the clinic, GCs are
frequently prescribed to cancer patients to alleviate the
acute toxicity of chemotherapy and to protect healthy tissue
(for example, bone marrow) against its long-term effects55.
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However, mounting clinical evidence has suggested that
GR activation may induce therapy resistance and is associated
with bad prognosis in solid tumours (for example,, basal-
like breast cancer and prostate cancer)25,47,48. Data presented
in this work not only fuel the concern raised over the use of
GCs as supportive co-medication in anti-cancer treatments,
but also provide novel mechanistic explanations of how GCs
lead to chemoresistance and tumour relapse by promoting the
unscheduled expansion of CSCs, a sub-population of cancer cells
that is intrinsically resistant to therapy and highly metastatic49.
In our experimental set-up, GCs activate YAP at doses that are
comparable to GCs plasma concentrations detected in cancer
patients receiving these hormones as palliative therapy56.
This supports the notion that the intrinsic ability of GCs to
aberrantly activate YAP and sustain CSCs may contribute to
GCs effects on chemotherapy response.
In line with our observations, it has been found that
RU486 treatment in mice sensitizes tumours from MDA-
MB-231 xenografts to PX treatment57. On the basis of our
results, it is conceivable that YAP inhibition and exhaustion
of CSCs could mediate this effect of RU486. Of note, an
ongoing Phase 1 clinical trial is testing the safety and tolera-
bility of RU486 in combination with nab-PX for advanced
ER-negative, PR-negative and HER2-negative breast cancer
(NCT01493310).
Our findings, as also reported in other studies16,58,59,
demonstrate the existence of a functional difference of
the Hippo pathway effectors YAP and TAZ. The major
structural differences between YAP and TAZ and their different
repertoire of post-translational modification and interacting
proteins60 might explain the divergent response of these two
proteins to GR stimulation.
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GCs are steroid hormones regulated by the circadian
rhythm and in response to several types of stress. The influence
of acute and chronic stress factors on the development
and progression of cancer has been a longstanding hypothesis
since ancient times. Epidemiological and clinical studies over the
past 30 years have provided evidence for a link between
dysregulation of neuroendocrine hormones, in particular cate-
cholamines and cortisol, and cancer progression58. The
unpredicted role of GCs on YAP activation unveiled by this
work suggests that a direct link between stress hormones
and oncogenes does exist and that, in some cases, oncogenes
may be activated in an endocrine manner.
In spite of their pro-oncogenic role in some solid cancers,
GCs have well-documented pro-apoptotic activity in cells
from haematological tumours and are considered as a first
line of defence in the treatment of different leukaemias59.
Interestingly, a recent study has reported YAP as an activator
of ABL1/p73-mediated apoptosis in the context of haematological
malignancies60,61. This evidence and our results may suggest
other possible connections between GCs and YAP via different
mechanisms.
In light of our findings, in fact, it is conceivable that
YAP activity could be involved in diverse GC-induced biological
responses, in both physiological and pathological conditions.
The metabolic syndrome (MetS), for example, might provide
another relevant pathological context where this relation is
worthy to be investigated. MetS is a clustering of condition
predisposing to cardiovascular disease and cancer, among other
co-morbidities62. Mounting clinical data and animal genetic
studies have strongly associated aberrant GC signalling with
diverse features of MetS63.
From a different point of view, the identification of GCs as
Hippo pathway regulators opens the doors to the exploration
of the potential role both of GCs in organ size control during
development and of YAP as part of the cellular physiological
response to GCs released under stress or circadian rhythm.
The functional role of the endocrine system in YAP activation
thus provides a novel conceptual framework to better understand
YAP/Hippo pathway functions and regulatory mechanisms
under a number of different signals and conditions.
Methods
Reagents and plasmids. The library of FDA-approved drugs (Screen-Well
FDA-Approved Drug Library, 640 chemical compounds dissolved at 10mM
in dimethylsulphoxide (DMSO)) was obtained from Enzo Life Sciences
(Enzo Life Sciences Inc.,Plymouth Meeting, PA, USA).
The following compounds were purchased from Sigma Aldrich: HC (H0888),
verteporfin (SML0534), PX (T7191), RU486 (Mifepristone; M8046), BM (B7005),
PF573228 (PZ0117). RGD is fibronectin tetrapeptide (H-Arg-Gly-Asp-Ser-OH)
from Santa Cruz (sc-202156).
Latrunculin A (sc-202691) was from Sigma, saracatinib (S1006) and
dasatinib (S1021) from Selleck.
8XGTII-Luc and the retroviral construct coding for Flag-YAP-5SA were
previously described16. Lentiviral constructs coding for short hairpin NR3C1
(GR) was from Sigma (Clone ID:NM_000176.2-6190s21c1).
Cell lines and isolation and purification of mammary epithelial cells. Cell
lines were obtained from American Type Culture Collection (ATCC) or from
other laboratories cooperating on the project. MDA-MB-231 and BT-549 were
cultured in DMEM supplemented with 10% FBS and antibiotics. MCF10A
MII cells were previously described16. Cells were obtained from ATCC or from
other laboratories cooperating on the project. Cells were subjected to STR
genotyping with PowerPlex 18D System and confirmed in their identity comparing
the results to reference cell databases (DMSZ, ATCC and JCRB databases).
All cell lines have been tested for mycoplasma contamination.
Mammary glands from 8 to 12-week-old virgin female mice were enzymatically
digested and single-cell suspensions of purified mammary epithelial cells
were obtained, as described64,65. Briefly, mammary glands from 8 to 12-week-old
virgin female mice were digested for 1–2 h at 37 C in Epi- Cult-B medium
(StemCell Technologies Inc, Vancouver, Canada) with 600Uml 1 collagenase
(Sigma-Aldrich, St Louis, MO, USA) and 200Uml 1 hyaluronidase (Sigma).
After lysis of the red blood cells with NH4Cl, the remaining cells were washed
with PBS/0.02% w/v EDTA to allow cell–cell contacts begin to break down. Cells
were then dissociated with 2ml trypsin 0.25%w/v, 0.2% w/v EDTA for 2min by
gentle pipetting, then incubated in 5mgml 1 Dispase II (Sigma) plus 1 mgml 1
DNase I (Sigma) for 5min followed by filtration through a 40 mM cell strainer
(BD Falcon, San Jose, CA, USA). Mammary epithelial cells were then purified
using the EasySep Mouse Mammary Stem Cell Enrichment Kit
(StemCell Technologies Inc).
High-content screening. For the screening experiments, MDA-MB-231
cells (3.0 103 per well) were seeded on black clear-bottom 384-well plates
(PerkinElmer). Twenty-four hours later, the FDA-approved drugs were transferred
robotically from library stock plates (0.1 and 1mM in DMSO) to the plates
containing the cells; controls were added to columns 1, 2, 23 and 24 of each plate.
Cells were fixed at 48 h after plating, that is, 24 h after addition of drugs, and
processed immediately for immunofluorescence. Briefly, cells were fixed with
4% paraformaldehyde for 15min, permeabilized with 0.1% Triton X-100 in
phosphate-buffered saline (PBS) solution for 10min, followed by 30min
blocking in 3% FBS. Cells were then incubated with a mouse antibody against
YAP (Santa Cruz Biotechnology) diluted in blocking solution for 1 h. Cells
were further washed with PBS and incubated for 1 h with a secondary
antibody conjugated to Alexa Fluor-594 (Life Technologies) and stained with
Hoechst 33342 (Life Technologies).
Image acquisition was performed using an ImageXpress Micro automated
high-content screening fluorescence microscope (Molecular Devices) at a
 10 magnification; a total of nine images were acquired per wavelength, well
and replicate, corresponding to ca. 4,500 cells analysed per experimental condition
and replicate. Image analysis to quantify the intensity of YAP and to identify
cells presenting predominantly nuclear YAP localization was performed using
the ‘Multi-Wavelength Cell Scoring’ and ‘Multi-Wavelength Translocation’
application modules implemented in MetaXpress software (Molecular Devices).
Screening was performed in duplicate, at two drug concentrations
(1 and 10mM); final concentration of DMSO in the culture medium was
1% (v/v) for all experimental conditions. The screening was performed at
the ICGEB High-Throughput Screening Facility (http://www.icgeb.org/high-
throughput-screening.html).
Transfections. siRNA transfections were done with Lipofectamine RNAi-MAX
(Life technologies) in antibiotics-free medium according to manufacturer
instructions. siRNAs were previously described18 and sequences are shown
in Supplementary Table 2.
Negative control siRNA was: AllStars negative control siRNA Qiagen
1027281.
DNA transfections were done with Lipofectamine LTX & Plus Reagent
(Invitrogen) or Lipofectamine RNAiMAX (Life Technologies) according to
manufacturer instructions. Lentiviral particles were prepared by transiently
transfecting HEK293T cells with lentiviral vectors together with packaging
vectors (pMD2-VSVG and psPAX2) using the standard calcium phosphate
method. Retroviruses were made by calcium phosphate transfection of
HEK293-GP packaging cells with the appropriate plasmids in combination
with pMD2ENV coding for envelope proteins, and collected 48 h later.
Infected cells were selected with puromycin 2mgml 1.
Luciferase assay. Luciferase assays were performed in MDA-MB-231 cells
and in BT-549 cells with the established YAP/TAZ-responsive reporter
8XGTII-Luc18. Luciferase reporters (300 ng cm 2) were transfected together
with CMV-Renilla (30 ng cm 2) to normalize for transfection efficiency. For
luciferase assays in siRNA-transfected cells, cells were first transfected with
the indicated siRNAs and, after 24 h, washed from transfection media,
transfected with plasmid DNA and collected 24 h later.
Soft agar assay. MDA-MB-231 cells in complete growth medium with
0.3% agar were layered onto 1% agar beds in six-well plates; complete medium
with 1 mM BM was added on top of cells and was replaced with fresh medium
twice a week for 15 days. Colonies larger than 100 mm in diameter were counted
as positive for growth.
Mammosphere assay. Mammosphere assays were performed as previously
described38. In brief, cells were treated with the indicated drugs for 5 days in
2-day culture. Then, cells were trypsinized, stained with trypan blue to check
cell viability and plated as single-cell suspension on ultra-low attachment plates
(Corning) in mammospheres growing medium36,38. When spheres reached
4100 mm size, spheres were counted, harvested with p1000, washed with
PBS, pelleted and dissociated with trypsin. Single cells where stained with trypan
blue, counted and reseeded for a second round of mammospheres formation.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14073 ARTICLE
NATURE COMMUNICATIONS | 8:14073 | DOI: 10.1038/ncomms14073 |www.nature.com/naturecommunications 11
Fluorescence-activated cell sorting. Fluorescence-activated cell sorting
assays were performed as previously described38. Cells were detached from plates
with trypsin, incubated in running buffer (PBS 1 , BSA 0.5% and EDTA 5mM)
with anti-human PE conjugated CD44 and anti-human fluorescein isothiocyanate-
conjuugated CD24 (BD Biosciences) and finally analysed with ARIA II cell
sorter (Beckton Dickinson).
Antibodies. Antibodies used for WB and immunofluorescence: anti-YAP is
sc101199 (1:1,000, Santa Cruz Biotechnology), anti- GR is BK3660S (1:1,000, Cell
Signaling), anti-actin is C11 (1:2,000, Sigma), anti-ANKRD1 is 11427-1-AP
(1:1,000, Proteintech (DBA), anti-pYAP (Ser127) is 4911S (1:1,000, Cell Signaling),
anti-WWTR1 is HPA007415 (1:1000, Sigma), phalloidin is A12379 (1:250, Alexa
Fluor), anti-PARP-85 is TB273 (1:500, Promega), anti-vinculin is V4505
(1:4,000, Sigma), anti-LATS1 is ab70562 (1:500, Abcam), phospho-LATS1
(Thr1079) is BK8654S (1:500, Cell Signaling), anti-FAK (C-20) is sc-558
(1:1,000, Santa Cruz), anti-FAK (phospho Y397) is ab81298 (1:1,000, Abcam),
anti-Src is BK2110S and anti-Phospho-Src (Tyr416) is BK2101S from Cell
Signaling (1:1,000), anti-FN1 is GTX112794 (1:1,000, GeneTex), anti-Slug is
C19G7 (1:500, Cell Signaling), anti-Mst1 is 3682S (1:500, Cell Signaling) and
anti-phospho-Mst1/2 (T183/T180) is 3681S (1:500, Cell Signaling).
Quantitative real-time PCR. Cells were collected in Qiazol lysis reagent (Qiagen)
for total RNA extraction, and contaminant DNA was removed by DNase
treatment. Quantitative PCR with reverse transcription analyses were carried out
on retrotranscribed complementary DNAs with Quantitect reverse transcription
kit (Qiagen) and analysed with Biorad CFX Manager software. Experiments
were performed at least three times, with duplicate replicates. Expression levels
are always given relative to histone H3. PCR oligo sequences for human samples
are shown in Supplementary Table 3.
Immunofluorescence and WB. Immunofluorescence staining was performed as
previously described11. Briefly, cells were fixed in 4% paraformaldehyde for
10min, washed in PBS, permeabilized with Triton 0.1% for 10min and blocked
in PBS FBS 3% for 30min. Antigen recognition was done by incubating
primary antibody for 1 h at 37 C and with goat anti-mouse Alexa Fluor 568
(Life Technologies) as secondary antibody for 30min a 37 C. Nuclei were
counterstained with Hoechst 33342 (Life Technologies). For extracellular
fibronectin staining, cells were plated onto glass coverslips without fibronectin
coating and immunofluorescence was performed without permeabilization.
WB analysis was performed as previously described11. Uncropped blots are
shown in Supplementary Fig. 7.
Chromatin immunoprecipitation. Following 6 h of treatment with BM 1 mM,
MDA-MB-231cells were crosslinked for 15min with 1% formaldehyde, neutralized
with 125mM glycine pH 2.5 and washed in PBS. Cells were scraped and
centrifuged at 1700 g for 10min at 4 C. Pellets were resuspended in 10ml
Chro-IP Lysis Buffer (50mM Hepes-KOH at pH 8; 1mM EDTA; 0.5mM EGTA;
140mM NaCl; 10% glycerol; 0.5% NP-40; 0.25% Triton X-100; protease inhibitor
cocktail (Sigma), 1mM PMSF, 5mM NaF) for 10min at 4 C. The crude nuclei
were collected by centrifugation (1300g for 5min at 4 C), resuspended in 10ml
wash buffer (10mM Tris-HCl at pH 8; 1mM EDTA; 0.5mM EGTA; 200mM
NaCl; protease inhibitor cocktail (Sigma), 1mM PMSF, 5mM NaF)for 5min at
4 C. Washed nuclei were centrifuged as described earlier and resuspended in 2ml
of RIPA 140mM (10mM Tris-HCl at pH 8; 1mM EDTA; 0.5mM EGTA;
140mM NaCl; 1% Triton X-100; 0.1% Na-deoxycholate; 0.1% SDS; protease
inhibitor cocktail (Sigma), 1mM PMSF, 5mM NaF). Samples were sonicated
(power setting 5) with a Misonix Microson in 10’’ bursts followed by 50’’ of cooling
on ice for a total sonication time of 2min per sample. Chromatin was precleared
for 1 h at 4 C with protein A/G PLUS-Agarose (Santa Cruz Biotechnologies)
and subsequently immunoprecipitated overnight at 4 C with 2 mg of anti-GR
(BK3660S, Cell Signaling); normal Rabbit IgG (sc-2027 Santa Cruz) were used
as negative control. DNA protein complexes were recovered with protein
A/G PLUS-Agarose and washed sequentially with RIPA 140mM buffer,
RIPA 250mM buffer (20mM Tris-HCl pH 7.5, 250mM NaCl, 1mM EDTA,
0.5% NP-40, 0.5% Na-deoxycholate and 0.1% SDS), LiCl solution (10mM Tris-HCl
pH 8.0, 1mM EDTA, 250mM LiCl, 0.5% NP-40 and 0.5% Na-Deoxycholate)
and TE. RNase treatment was performed in TE for 30min at 37 C and to reverse
cross-linking samples were treated overnight at 68 C adding an equal volume of
proteinase K solution (200mM NaCl, 1% SDS and 0.3mgml 1 proteinase K).
In parallel, inputs were treated in the same way. After phenol/chloroform
extraction and ethanol precipitation samples were resuspended in H2O.
Real-time PCR was performed by using iTaq Universal SYBR Green Supermix
(BIORAD). Primer sequences were retrieved from ENCODE data and are shown
in the Methods section (Quantitative real-time PCR). Promoter occupancy was
calculated as the fold increase of normalized immunoprecipitated chromatin
over the control IgG with the 2 DDCt method.
Biostatistical analysis. RNA-Seq data of MDA-MB-231 cells treated with
DM were retrieved from GSE56022 (ref. 25). We defined GR target genes as
genes with a fold change 41.3 and an increase in expression 41 RPKM
(reads per kilobase per million mapped reads) in at least one replicate of cells
treated with 100 nM DM for 4 h as compared with cells treated with vehicle.
Enrichment analysis was conducted using David functional annotation.
ChIP-Seq data for GR in A549 cells treated with 100 nM DM were retrieved
from ENCODE66.
The metadaset of breast cancer gene expression profiles has been created
starting from a collection of 4,640 samples from 27 major data sets, comprising
microarray data of breast cancer samples annotated with histological tumour
grade and clinical outcome17,67. The collection was normalized and annotated
with clinical information as described in ref. 67. This resulted in a compendium
comprising 3,661 unique samples from 25 independent cohorts. Intrinsic
molecular subtypes were assigned using the intrinsic.cluster.predict function of
genefu R package68 using the ‘50 intrinsic gene list’ as proposed by Parker and
colleagues (PAM50; ref. 69).
To identify two groups of tumours with either high or low GR activity
signature, we used the classifier described in ref. 70. Tumours were classified
as GR signature low if the combined score was lower than the first quartile of
the score distribution and as GR signature high if the combined score was higher
than the third quartile of the score distribution. This classification was applied to
expression values of the metadata set.
GR activity signatures were derived from GCs-induced genes in MDA-MB-231
and A549 cells25,40. Briefly, to derive the GR signature from the data of Chen
et al.25 we started from the list of GR target genes in MDA-MB-231 cells
treated with DM and further refined it selecting only those genes overexpressed
in cells treated with DM (fold change 42 and an RPKM difference Z2), but
not in cells treated with Compound A (fold change r2) in the comparison
with cells treated with vehicle at 4 h (ref. 25). To derived the GR signature in
A549 lung adenocarcinoma epithelial cells40, we downloaded the raw data of
GSE17307 from Gene Expression Omnibus and converted probe level signals
to expression values using robust multi-array average procedure RMA71 of
Bioconductor affy package. Differentially expressed genes were identified
using Significance Analysis of Microarray algorithm coded in the
samr R package72. In SAM, we estimated the percentage of false-positive
predictions (that is, false discovery rate, FDR) with 100 permutations
and defined GC-induced genes selecting, at a confidence level of 95%
(FDRr5%), those probes with a fold change Z2 in cells treated with
DM (for 6 h) and with a negative fold change in cells treated with DM and
GR antagonist mifepristone. The full list of genes enlisted in the GR activity
signatures is provided in Supplementary Table 1.
Average stem cell and Yap signature expression has been calculated as the
standardized average expression of all signature genes in sample subgroups
(for example, GR activity high/low). As stem cell signatures we used the lists of
genes of Shipitsin et al.41 and of Farmer et al.42 The YAP activity signature is
composed of a selection of genes that have been found activated by YAP
overexpression in human mammary cells (MCF10A; ref. 73).
To evaluate the prognostic value of the GR signature, we estimated, using
the Kaplan–Meier method, the probabilities that patients would remain free of
metastatic events. To confirm these findings, the Kaplan–Meier curves were
compared using the log-rank (Mantel–Cox) test. P values were calculated according
to the standard normal asymptotic distribution. Survival analysis was performed in
GraphPad Prism.
The sample size was chosen to include at least three biological replicates
with two technical replicates each. Experiments for which we showed
representative images were performed successfully at least 3 independent times.
No samples or animal were excluded from the analysis.
No statistical method was used to predetermine the sample size for animal
studies. Standard laboratory practice randomization procedure was used for cell
line groups and animals of the same age and sex. The investigators were not
blinded to allocation during experiments and outcome assessment. All P values
were determined using two-tailed t -tests and statistical significance was set at
P¼ 0.05. The variance was similar between groups that we compared.
Mice and animal care. Eight-week-old C57BL/6 female mice were maintained
in a specific pathogen free animal facility. Mice received a single intraperitoneal
bolus of DM sulfate (20mg kg 1) at time 0, to be sacrified 16 h later for
mammary gland collection. Procedures involving animals and their care
were in conformity with institutional guidelines (D.L. 116/92 and 26/2014,
and subsequent implementing circulars) and all experimental protocols
were approved by the ethical Committee of the University of Padua (CEASA).
For limiting dilution experiments serial dilutions of MDA-MB-231-shCTL
or MDA-MB-231-shGR cells ranging from 125,000 to 15,000 cells were
resuspended in 100ml of DMEM, and injected into the mammary fat pad
of previously anaesthetized (1–3% isoflurane, Merial Italia) NSG female
mice. Tumour growth at the injection site was monitored by caliper
measurements and tumour volume was calculated using the formula:
Tumour volume (mm3)¼D d2/2, where D and d are the longest and the
shortest diameters, respectively.
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Data availability. The authors declare that the main data supporting the
findings of this study are available within the article and its Supplementary
Information Files. Extra data are available from the corresponding author on
request.
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